(News Bulletin 247) – Oddo BHF maintains its ‘outperformance’ rating on the Valbiotis share, with a price target raised from 10 to 11.5 euros.
As a reminder, Valbiotis published its phase II/III clinical results of TOTUM-63 in prediabetes earlier this week. These turn out to be positive demonstrating a statistically significant reduction in patients’ fasting blood glucose vs. placebo.
According to Oddo BHF, the commercialization of TOTUM-63 is already planned, given its health nutrition status, in 2024, in collaboration with Nestlé Health Science.
‘Thus we see the clinical and regulatory now secure. Due to its profile, Valbiotis combines the opportunities of a biotechnology company with a lower development risk, which is more attractive,’ concludes the broker.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
